伊朗高血压治疗的直接成本
Mahmoud Zamandi1, Rajabali Daroudi1, Ali Akbari Sari1
1Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Iranian journal of public health
|November 30, 2023
概括
伊朗高血压治疗的直接成本很大,在2020年达到8754万美元. 早期发现和治疗高血压对于减少并发症和医疗费用至关重要.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 心血管疾病管理管理
背景情况:
- 高血压是一个严重的公共卫生问题,可能带来严重的后果.
- 了解与高血压治疗相关的直接成本对于资源配置和政策制定至关重要.
研究的目的:
- 调查和量化伊朗高血压治疗的直接经济成本.
- 提供对伊朗人口高血压管理的经济概述.
主要方法:
- 利用文献综述和STEPS调查来确定2020年伊朗高血压发病率,流行率和治疗覆盖率.
- 应用国家标准的高血压治疗方案来估计所需的医疗服务,包括患者访问,药物和实验室测试.
- 使用所有已识别的服务的国家参考成本计算疾病总成本.
主要成果:
- 大约有2339万人患有中度静缩血压 (120-139毫米/升),1460万人患有严重的血压 (≥140毫米/升).
- 只有39.8%的高血压患者接受治疗.
- 高血压治疗的总直接成本为19006.08亿伊朗里亚尔 (87.54亿美元),其中83.40%归因于现有病例,16.60%归因于新病例. 患者访问是最大的成本组成部分 (56%),其次是药物 (35.51%) 和实验室测试 (8.49%).
结论:
- 高血压在伊朗具有相当大的患病率和经济负担.
- 实施高血压的早期检测和及时治疗策略可以显著减轻其并发症和相关治疗成本.
相关概念视频
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Errors occurring during blood pressure monitoring
735
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
735
Alterations in Blood Pressure
1.2K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors
637
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
637
Antihypertensive Drugs: Action of Diuretics
786
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
786
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174


